about
Nonalcoholic fatty liver disease, portal vein thrombosis and coagulation: more questions than answers?A Randomized Controlled Trial of Procedural Techniques for Large Volume Paracentesis.Spontaneous bacterial peritonitis prevalence in pre-transplant patients and its effect on survival and graft loss post-transplant.Reversal of direct oral anticoagulants for liver transplantation in cirrhosis: A step forward.Direct Oral Anticoagulants in Cirrhosis.Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation.Anticoagulant Therapy in Patients with Cirrhosis.Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis.Dismantling the myth of "autoanticoagulation" in cirrhosis: an old dogma dies hard.Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding.Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization.Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.Procoagulant therapeutics in liver disease: a critique and clinical rationale.Gastroparesis in type 2 diabetes mellitus: prevalence, etiology, diagnosis, and treatment.Decreased Portal Vein Velocity is Predictive of the Development of Portal Vein Thrombosis: a Matched Case-Control Study.Diagnostic testing for decompensated cirrhosis-striking a better balance in a new era.Treating thrombosis in cirrhosis patients with new oral agents: ready or not?Prediction of bleeding in cirrhosis patients: Is the forecast any clearer?The Optimal Transfusion Strategy in Liver Transplantation: The Quest Continues.Changes in hemostasis in liver disease.Mechanisms of enhanced thrombin generating capacity in patients with cirrhosis.Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis.Thrombosis of the Portal Venous System in Cirrhotic vs. Non-Cirrhotic PatientsViscoelastic Testing in Liver DiseaseVenous thromboembolism in patients with liver diseases: commentManagement of nosocomial spontaneous bacterial peritonitis: A complex and moving targetAnticoagulación en la trombosis de la vena porta en la cirrosisAnticoagulation for portal vein thrombosis in cirrhosisManagement of disordered hemostasis and coagulation in patients with cirrhosisMacrosteatotic Allografts and Obese Recipients Have Nearly Equal Negative Impact on Liver Transplant SurvivalEpidemiology and Effects of Bacterial Infections in Patients With Cirrhosis WorldwideClinical Cirrhosis Dilemmas: Survey of Practice from the 7th International Coagulation in Liver Disease ConferenceDiagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without CirrhosisOveruse of venous thromboembolism prophylaxis among hospitalized patients with liver diseaseAcute kidney injury is associated with low factor XIII in decompensated cirrhosisElectronic Consultations to Hepatologists Reduce Wait Time for Visits, Improve Communication, and Result in Cost SavingsCoagulation Pathways, Hemostasis, and Thrombosis in Liver Failure
P50
Q30252457-E43E63BC-A139-4FA8-9420-D924D9CBE3DDQ30268485-1A943F19-82E5-487F-A8BE-1F3E6573BCBCQ30275010-15ACBF0E-9C56-4FD4-9885-4204F567D9E1Q30275149-4F66A361-342A-4963-BF82-0934DCD9C2FDQ30277086-E517B483-2BA7-4158-B6C3-5B7E214480BFQ30277819-6A47E5E1-051E-4776-98B5-D2784D53A9A7Q30279225-8E62B652-4F33-4747-9D27-03FD480741DFQ30301355-A519D22F-3464-4332-BD0F-59F4F2195EE0Q30455384-25F9A126-8369-49FD-9955-B68909628546Q30456742-E5960432-27E1-442D-A540-B5A5761D22B6Q30458237-245D9D12-EDA0-41A0-8FD0-48FD6DB2802CQ30458532-7BA9130D-B008-4A92-88D6-035B08CCB0ADQ30458618-C2F50DAB-CD8B-4159-B189-D75D96199142Q36947379-45EBB954-45D1-4097-BE35-94DD809EC842Q38668946-112A3C41-21DF-48EF-AA1B-7B1A3401AD8EQ44957239-007C7F31-A395-4AF4-8A9A-EAF261C89387Q44998149-54FAFCF2-23D2-45B2-AFD2-FB58159B98C2Q45024104-FF4B092B-4534-481F-A36B-E4A8D7173FC5Q45070658-8A80A09C-3373-4F09-B3BB-CE5BC48707EFQ45073437-91342882-CBB0-4EBB-A85B-3AB89C58CC90Q52327028-1FBAAE4C-1A59-418F-B5CA-4976DA6E004BQ55342502-C0AB71B3-6FF4-4601-9FF9-0BBCE37D1702Q56376784-59C877A0-387B-4914-94A2-0C4730CD5991Q56381039-619BF3F9-A095-47B4-9EDC-EB77F7C09030Q58546400-E43942D5-902D-4075-8775-A780500A248CQ63977664-23688F59-5DDB-4075-BE4E-FC7BB629EAC6Q63978904-00998CA9-F2CB-462C-B491-0EB5F2C3A1A8Q63979056-2F63182B-AF62-4828-AF11-5AD33312A247Q63980059-F64F7EF9-DC9B-43B7-9736-5A6851670556Q90437140-E34E9327-0E52-4C04-A491-0DC26A1B1DB9Q90538864-1652A362-68D3-4464-BE4B-1AD048249B86Q90813888-AFFC2391-FFCB-4542-A31F-521DADEA1EE9Q91641195-E5A6CD0B-D309-4C34-8D31-A6D421F38A0BQ91662392-C1864CBB-7ADD-41EC-BAF0-7BD7C6A9D7C5Q92985199-0D898D18-9370-49FE-B9A3-EE5848105B05Q93190724-08402212-4FA3-4EF8-ADDF-AAE8EFCCEB53Q93372904-5A4E6ADA-42D8-4BC3-8C18-973154422291
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Nicolas Intagliata
@en
Nicolas Intagliata
@nl
type
label
Nicolas Intagliata
@en
Nicolas Intagliata
@nl
prefLabel
Nicolas Intagliata
@en
Nicolas Intagliata
@nl
P31
P496
0000-0001-6375-8458